Pfizer gives back two nanobodies to Ablynx
New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage trial in patients with rheumatoid arthritis in May, and PF-05230905, which is in Phase I trials. Originally Ablynx, which is using the DNA of camels and llamas to develop a new class of drugs, had made an agreement with US-pharma company Wyeth to outlicense the two nanobodies. Wyeth was bought by Pfizer, and the new owners now disentangle themselves from old liabilities as they see it. As compensation for terminating the contract, Pfizer will not only hand over all intellectual property relating to the anti-TNF-alpha programmes to Ablynx, but also all data of existing clinical trial supplies of ATN-103 and PF-05230905, assay methods and manufacturing processes for use in future development activities. In return, Ablynx will share with Pfizer up to $50 million in future milestone payments it may receive from other third-party deals related to the products, as well as royalties on sales.